Literature DB >> 11165470

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

P Gilbert1, S Self, M Rao, A Naficy, J Clemens.   

Abstract

A key component in the evaluation of efficacy of a vaccine to protect against disease caused by an antigenically diverse infectious pathogen in a preventative vaccine trial is assessing how vaccine-induced protection depends on genotypic and phenotypic variations of the exposing pathogen. This assessment is made by comparing pathogen isolates between infected vaccinated subjects and infected unvaccinated subjects. A survey of efficacy trial reports reveals a lack of systematic, quantitative investigation in this question. Analysis tools for testing if vaccine protection against disease is superior against some pathogen strains, and for estimating the magnitude of this differential vaccine protection, are described. The broad applicability of the methods is illustrated through analysis of isolates taken from persons infected while participating in vaccine trails for cholera, HIV-1, hepatitis B, rotavirus, and pneumococcus. These analyses reveal intriguing trends for Genentech's monovalent rgp120 HIV-1 vaccine, for two whole-killed-cell oral cholera vaccines, and for other vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165470     DOI: 10.1016/s0895-4356(00)00258-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  25 in total

1.  Tests for comparing mark-specific hazards and cumulative incidence functions.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Lifetime Data Anal       Date:  2004-03       Impact factor: 1.588

2.  Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.

Authors:  Peter B Gilbert; Ying Huang
Journal:  Epidemiol Methods       Date:  2016-01-23

3.  Invited commentary: Evaluating vaccination programs using genetic sequence data.

Authors:  M Elizabeth Halloran; Edward C Holmes
Journal:  Am J Epidemiol       Date:  2009-11-12       Impact factor: 4.897

4.  Estimating and Testing Vaccine Sieve Effects Using Machine Learning.

Authors:  David Benkeser; Peter B Gilbert; Marco Carone
Journal:  J Am Stat Assoc       Date:  2019-04-03       Impact factor: 5.033

5.  Sieve analysis using the number of infecting pathogens.

Authors:  Dean Follmann; Chiung-Yu Huang
Journal:  Biometrics       Date:  2017-12-14       Impact factor: 2.571

6.  Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.

Authors:  Fang-Hua Lee; Rosemarie Mason; Hugh Welles; Gerald H Learn; Brandon F Keele; Mario Roederer; Katharine J Bar
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

Authors:  V Novitsky; U R Smith; P Gilbert; M F McLane; P Chigwedere; C Williamson; T Ndung'u; I Klein; S Y Chang; T Peter; I Thior; B T Foley; S Gaolekwe; N Rybak; S Gaseitsiwe; F Vannberg; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Authors:  James G Kublin; Cecilia A Morgan; Tracey A Day; Peter B Gilbert; Steve G Self; M Juliana McElrath; Lawrence Corey
Journal:  Clin Investig (Lond)       Date:  2012-03

Review 9.  Sieve analysis in HIV-1 vaccine efficacy trials.

Authors:  Paul T Edlefsen; Peter B Gilbert; Morgane Rolland
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

10.  Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications.

Authors:  Amed Ouattara; Shannon Takala-Harrison; Mahamadou A Thera; Drissa Coulibaly; Amadou Niangaly; Renion Saye; Youssouf Tolo; Sheetij Dutta; D Gray Heppner; Lorraine Soisson; Carter L Diggs; Johan Vekemans; Joe Cohen; William C Blackwelder; Tina Dube; Matthew B Laurens; Ogobara K Doumbo; Christopher V Plowe
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.